Point looks to turn the tables on Novartis
Conventional wisdom says manufacturing takes second place to clinical development, but Point turned that on its head, and now a big catalyst approaches.
Asco-GU – Talzenna remains a wait-and-see story in prostate cancer
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.
Pfizer reignites the Parp biomarker debate
Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.
FDA scrutiny now hits Parp inhibitors
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
